Treace Medical Concepts, Inc.
TMCINASDAQHealthcare● Active
$3.53
+$0.02(+0.57%)
Market Cap$229001605
P/E Ratio—
52W High$7.78
52W Low$1.17
Treace Medical Concepts, Inc. (TMCI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TMCI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.28
Est. -$0.31 · +9.7%
Revenue
$0.05B
Est. $0.05B · +2.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
TMCI reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.30 | — | — | — | $0.04B | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$0.31 | -$0.28 | +9.7% | $0.05B | $0.05B | +2.7% |
| ▲ Q1 FY2026 | Feb 27, 2026 | -$0.15 | -$0.12 | +21.0% | $0.06B | $0.06B | +1.1% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.28 | -$0.26 | +7.1% | $0.05B | $0.06B | -18.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.29 | -$0.28 | +3.5% | $0.05B | $0.05B | -5.0% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.31 | -$0.25 | +19.4% | $0.05B | $0.05B | +6.2% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.04 | -$0.01 | +75.0% | $0.07B | $0.07B | +2.3% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.27 | -$0.25 | +7.4% | $0.05B | $0.07B | -32.6% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.30
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.28
EPS Est.
-$0.31
EPS Surpr.
+9.7%
Revenue
$0.05B
Q1 FY2026
Feb 27, 2026Beat
EPS Actual
-$0.12
EPS Est.
-$0.15
EPS Surpr.
+21.0%
Revenue
$0.06B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.28
EPS Surpr.
+7.1%
Revenue
$0.05B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.29
EPS Surpr.
+3.5%
Revenue
$0.05B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.31
EPS Surpr.
+19.4%
Revenue
$0.05B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.04
EPS Surpr.
+75.0%
Revenue
$0.07B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.25
EPS Est.
-$0.27
EPS Surpr.
+7.4%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.08 | $0.08 | $0.08 | 1 |
| Q3 FY2028 | $-0.16 | $-0.15 | $-0.15 | 1 |
| Q2 FY2028 | $-0.21 | $-0.20 | $-0.20 | 1 |
| Q1 FY2028 | $-0.20 | $-0.19 | $-0.19 | 1 |
| Q4 FY2027 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2027 | $-0.22 | $-0.22 | $-0.21 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +9.7% | $1.92 | $2.01 | +4.69% |
| ▲ Q1 FY2026 | Feb 27, 2026 | +21.0% | $2.10 | $1.86 | -11.43% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +7.1% | $6.25 | $6.23 | -0.32% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +3.5% | $5.47 | $5.68 | +3.84% |
| ▲ Q2 FY2025 | May 8, 2025 | +19.4% | $7.20 | $7.54 | +4.72% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +75.0% | $9.70 | $9.13 | -5.88% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +7.4% | $5.43 | $5.76 | +6.08% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -17.2% | $6.33 | $6.66 | +5.21% |
Q2 FY2026+4.69%
Report Date
May 8, 2026
EPS Beat/Miss
+9.7%
Price Before
$1.92
Price After
$2.01
Q1 FY2026-11.43%
Report Date
Feb 27, 2026
EPS Beat/Miss
+21.0%
Price Before
$2.10
Price After
$1.86
Q4 FY2025-0.32%
Report Date
Nov 6, 2025
EPS Beat/Miss
+7.1%
Price Before
$6.25
Price After
$6.23
Q3 FY2025+3.84%
Report Date
Aug 7, 2025
EPS Beat/Miss
+3.5%
Price Before
$5.47
Price After
$5.68
Q2 FY2025+4.72%
Report Date
May 8, 2025
EPS Beat/Miss
+19.4%
Price Before
$7.20
Price After
$7.54
Q1 FY2025-5.88%
Report Date
Feb 27, 2025
EPS Beat/Miss
+75.0%
Price Before
$9.70
Price After
$9.13
Q4 FY2024+6.08%
Report Date
Nov 5, 2024
EPS Beat/Miss
+7.4%
Price Before
$5.43
Price After
$5.76
Q3 FY2024+5.21%
Report Date
Aug 6, 2024
EPS Beat/Miss
-17.2%
Price Before
$6.33
Price After
$6.66
Avg Beat Reaction+0.24%
Avg Miss Reaction+5.21%
Beat Rate7 / 8 quarters
Largest Move-11.43% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TMCI ends December
Treace Medical Concepts, Inc. (TMCI) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.28 — beating the analyst consensus of $-0.31 by +9.7%. TMCI has beaten EPS estimates for 7 consecutive quarters. The next TMCI earnings date is expected around September 1, 2026.
Each quarter, investors track TMCI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TMCI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TMCI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TMCI earnings · 5 questionsTreace Medical Concepts, Inc.'s next earnings report is expected around September 1, 2026. TMCI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TMCI historically reports after market close (AMC).
TMCI earnings datewhen is TMCI earningsTMCI next earnings datewhen does TMCI report earningsTMCI earnings calendar
▸ Source: FMP · Treace Medical Concepts, Inc. SEC filings · US GAAP · Treace Medical Concepts, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026